These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21502951)

  • 81. Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats.
    Choi M; Lee SH; Chang HL; Son H
    Biochim Biophys Acta; 2016 Jul; 1862(7):1247-54. PubMed ID: 27063455
    [TBL] [Abstract][Full Text] [Related]  

  • 82. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.
    Liu RJ; Fuchikami M; Dwyer JM; Lepack AE; Duman RS; Aghajanian GK
    Neuropsychopharmacology; 2013 Oct; 38(11):2268-77. PubMed ID: 23680942
    [TBL] [Abstract][Full Text] [Related]  

  • 83. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
    Autry AE; Adachi M; Nosyreva E; Na ES; Los MF; Cheng PF; Kavalali ET; Monteggia LM
    Nature; 2011 Jun; 475(7354):91-5. PubMed ID: 21677641
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Synaptic dysfunction in depression: potential therapeutic targets.
    Duman RS; Aghajanian GK
    Science; 2012 Oct; 338(6103):68-72. PubMed ID: 23042884
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.
    Beurel E; Grieco SF; Jope RS
    Pharmacol Ther; 2015 Apr; 148():114-31. PubMed ID: 25435019
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
    Niciu MJ; Henter ID; Luckenbaugh DA; Zarate CA; Charney DS
    Annu Rev Pharmacol Toxicol; 2014; 54():119-39. PubMed ID: 24392693
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.
    Chiu CT; Scheuing L; Liu G; Liao HM; Linares GR; Lin D; Chuang DM
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548109
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice.
    Ma XC; Dang YH; Jia M; Ma R; Wang F; Wu J; Gao CG; Hashimoto K
    PLoS One; 2013; 8(2):e56053. PubMed ID: 23390559
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Antidepressant mechanism of ketamine: perspective from preclinical studies.
    Scheuing L; Chiu CT; Liao HM; Chuang DM
    Front Neurosci; 2015; 9():249. PubMed ID: 26257598
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β.
    Duman RS; Aghajanian GK
    Neuropsychopharmacology; 2014 Jan; 39(1):233. PubMed ID: 24317309
    [No Abstract]   [Full Text] [Related]  

  • 92. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
    De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
    Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.
    King MK; Pardo M; Cheng Y; Downey K; Jope RS; Beurel E
    Pharmacol Ther; 2014 Jan; 141(1):1-12. PubMed ID: 23916593
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An excitatory synapse hypothesis of depression.
    Thompson SM; Kallarackal AJ; Kvarta MD; Van Dyke AM; LeGates TA; Cai X
    Trends Neurosci; 2015 May; 38(5):279-94. PubMed ID: 25887240
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mechanisms of ketamine action as an antidepressant.
    Zanos P; Gould TD
    Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
    Yang Y; Cui Y; Sang K; Dong Y; Ni Z; Ma S; Hu H
    Nature; 2018 Feb; 554(7692):317-322. PubMed ID: 29446381
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.
    Beurel E; Grieco SF; Amadei C; Downey K; Jope RS
    Bipolar Disord; 2016 Sep; 18(6):473-480. PubMed ID: 27687706
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Convergent Mechanisms Underlying Rapid Antidepressant Action.
    Zanos P; Thompson SM; Duman RS; Zarate CA; Gould TD
    CNS Drugs; 2018 Mar; 32(3):197-227. PubMed ID: 29516301
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prefrontal cortex molecular clock modulates development of depression-like phenotype and rapid antidepressant response in mice.
    Sarrazin DH; Gardner W; Marchese C; Balzinger M; Ramanathan C; Schott M; Rozov S; Veleanu M; Vestring S; Normann C; Rantamäki T; Antoine B; Barrot M; Challet E; Bourgin P; Serchov T
    Nat Commun; 2024 Aug; 15(1):7257. PubMed ID: 39179578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.